IgA Vasculitis Following COVID-19 Vaccination : A French Multicenter Case Series Including 12 Patients
Copyright © 2023 by the Journal of Rheumatology..
OBJECTIVE: The worldwide coronavirus disease 2019 (COVID-19) vaccination campaign triggered several autoimmune diseases. We hereby aimed to describe IgA vasculitis (IgAV) following COVID-19 vaccination.
METHODS: We conducted a national, multicenter, retrospective study in France of new-onset adult IgAV diagnosis following COVID-19 vaccination.
RESULTS: In total, 12 patients with new-onset IgAV were included. Of these, 5 (41.7%) were women, and the median age was 52.5 (IQR 30.75-60.5) years. Of the 12 patients, 10 had received an mRNA vaccine and 2 had received a viral vector vaccine. The median time from vaccination to onset of symptoms was 11.5 (IQR 4.25-21.25) days. Vasculitis occurred after the first vaccine dose in most patients (n = 8). All patients had skin involvement, with skin necrosis in 4 patients. In total, 7 patients had joint involvement and 2 had arthritis. A total of 4 patients had nonsevere gastrointestinal involvement and 2 had nonsevere renal involvement. The median C-reactive protein level was 26 (IQR 10-66.75) mg/L, the median creatininemia level was 72 (IQR 65-81) μmol/L, and 1 patient had an estimated glomerular filtration rate of less than 60 mL/min at management. All patients received treatment, including 9 patients (75%) who received glucocorticoids. In total, 5 patients received a vaccine dose after developing IgAV, 1 of whom experienced a minor cutaneous relapse.
CONCLUSION: The baseline presentation of IgAV following COVID-19 vaccination was mild to moderate, and outcomes were favorable. Thus, a complete COVID-19 vaccination regimen should be completed in this population. Of note, a fortuitous link cannot be ruled out, requiring a worldwide pharmacovigilance search to confirm these findings.
| Errataetall: |
CommentIn: J Rheumatol. 2023 Aug;50(8):1092. - PMID 36921974 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
The Journal of rheumatology - 50(2023), 2 vom: 01. Feb., Seite 252-257 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramdani, Yanis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 03.02.2023 Date Revised 03.08.2023 published: Print-Electronic CommentIn: J Rheumatol. 2023 Aug;50(8):1092. - PMID 36921974 Citation Status MEDLINE |
|---|
| doi: |
10.3899/jrheum.220545 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348329997 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348329997 | ||
| 003 | DE-627 | ||
| 005 | 20231226035923.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3899/jrheum.220545 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348329997 | ||
| 035 | |a (NLM)36319000 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramdani, Yanis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IgA Vasculitis Following COVID-19 Vaccination |b A French Multicenter Case Series Including 12 Patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.02.2023 | ||
| 500 | |a Date Revised 03.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Rheumatol. 2023 Aug;50(8):1092. - PMID 36921974 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by the Journal of Rheumatology. | ||
| 520 | |a OBJECTIVE: The worldwide coronavirus disease 2019 (COVID-19) vaccination campaign triggered several autoimmune diseases. We hereby aimed to describe IgA vasculitis (IgAV) following COVID-19 vaccination | ||
| 520 | |a METHODS: We conducted a national, multicenter, retrospective study in France of new-onset adult IgAV diagnosis following COVID-19 vaccination | ||
| 520 | |a RESULTS: In total, 12 patients with new-onset IgAV were included. Of these, 5 (41.7%) were women, and the median age was 52.5 (IQR 30.75-60.5) years. Of the 12 patients, 10 had received an mRNA vaccine and 2 had received a viral vector vaccine. The median time from vaccination to onset of symptoms was 11.5 (IQR 4.25-21.25) days. Vasculitis occurred after the first vaccine dose in most patients (n = 8). All patients had skin involvement, with skin necrosis in 4 patients. In total, 7 patients had joint involvement and 2 had arthritis. A total of 4 patients had nonsevere gastrointestinal involvement and 2 had nonsevere renal involvement. The median C-reactive protein level was 26 (IQR 10-66.75) mg/L, the median creatininemia level was 72 (IQR 65-81) μmol/L, and 1 patient had an estimated glomerular filtration rate of less than 60 mL/min at management. All patients received treatment, including 9 patients (75%) who received glucocorticoids. In total, 5 patients received a vaccine dose after developing IgAV, 1 of whom experienced a minor cutaneous relapse | ||
| 520 | |a CONCLUSION: The baseline presentation of IgAV following COVID-19 vaccination was mild to moderate, and outcomes were favorable. Thus, a complete COVID-19 vaccination regimen should be completed in this population. Of note, a fortuitous link cannot be ruled out, requiring a worldwide pharmacovigilance search to confirm these findings | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a Henoch-Schönlein purpura | |
| 650 | 4 | |a IgA vasculitis | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Bettuzzi, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Bouznad, Amel |e verfasserin |4 aut | |
| 700 | 1 | |a Delaitre, Léa |e verfasserin |4 aut | |
| 700 | 1 | |a Nassarmadji, Kladoum |e verfasserin |4 aut | |
| 700 | 1 | |a Didier, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Carle |e verfasserin |4 aut | |
| 700 | 1 | |a Liozon, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Tieu, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Richard-Colmant, Gaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Terrier, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Moulis, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Lafaurie, Margaux |e verfasserin |4 aut | |
| 700 | 1 | |a Pillebout, Evangeline |e verfasserin |4 aut | |
| 700 | 1 | |a Maillot, François |e verfasserin |4 aut | |
| 700 | 1 | |a Audemard-Verger, Alexandra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of rheumatology |d 1983 |g 50(2023), 2 vom: 01. Feb., Seite 252-257 |w (DE-627)NLM000019593 |x 1499-2752 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:2 |g day:01 |g month:02 |g pages:252-257 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3899/jrheum.220545 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 2 |b 01 |c 02 |h 252-257 | ||